Abstract | BACKGROUND: METHODS: RESULTS: Twenty patients were enrolled from 2003 to 2006. The median age was 51 (29-70) year-old. Eight patients were premenopausal. Ten patients had positive hormone receptors. Four patients had HER2 positive receptor. Nineteen patients completed six cycles of TEC chemotherapy. The pathologic complete response rate was 25%. Eight of sixteen patients with N1-3 disease had pathological negative lymph nodes. With a median follow up of 57.5 (16-71) months, four patients relapsed including one death from recurrence. The estimated 5 year relapse-free survival was 79.3% and the 5-year overall survival was 94.7%. No patient had cardiac failure or death during treatment. The most common grade 3-4 toxicity was neutropenia (35%). CONCLUSION:
|
Authors | Xin Yao, Janet Hosenpud, Christopher R Chitambar, John Charlson, Yee Chung Cheng |
Journal | Journal of Cancer
(J Cancer)
Vol. 3
Pg. 145-51
( 2012)
ISSN: 1837-9664 [Electronic] Australia |
PMID | 22481980
(Publication Type: Journal Article)
|